
How investing $33 a day could make you a millionaire by retirement
Here's a look at how you might become a millionaire by retirement by saving and investing just $33 per day.
How $33 per day can get you to $1 million − or more
An article like this can be very eye-opening and instructive, but it's hard to offer one table that applies equally well to everyone. Let's start with the table − and I'll add a lot of caveats and considerations after it.
Investing $12,000 Annually for:
Growing at 8% Annually
Growing at 10% Annually
Growing at 12% Annually
Five years
$76,032
$80,587
$85,382
10 years
$187,746
$210,374
$235,855
15 years
$351,892
$419,397
$501,039
20 years
$593,076
$756,030
$968,385
25 years
$947,452
$1,298,181
$1,792,007
30 years
$1,468,150
$2,171,321
$3,243,511
35 years
$2,233,226
$3,577,522
$5,801,557
40 years
$3,357,372
$5,842,222
$10,309,707
I used several growth rates in that table, because the stock market can be somewhat unpredictable. Over many decades, the stock market has averaged annual returns of close to 10%. But over your investing period, it might average more -- or less.
So for best results, go ahead and aim and hope for high returns, but prepare for lower ones, just in case.
How much per day do you need to save and invest?
You'll notice that per the table, it may take you 20 or 25 years to become a millionaire, saving and investing $33 per day, on average. That might not be good enough, if you're, say, 55 years old already.
So check out the table, detailing how much you need to save to retire with $1 million -- if you want to retire at 65 and your money grows at 8% annually:
Starting Age
Monthly Savings Needed
Daily Savings Needed
25
$325
$11
30
$485
$16
35
$740
$24
40
$1,140
$37
45
$1,825
$60
50
$3,070
$101
55
$5,760
$189
How should you invest your money?
So now that you have a rough idea of how much you should be saving and investing, how should you be investing? Well, arguably the simplest, most effective strategy is just to invest in a low-fee, broad-market index fund, such as one that tracks the S&P 500.
Since the S&P 500 has averaged annual returns close to 10% (ignoring inflation) over long periods, you have a fighting chance over your investment period to achieve an average annual gain of perhaps 8% or 10% − or possibly more.
Index funds make investing easy, with an S&P 500 index fund, for example, such as the Vanguard S&P 500 ETF, instantly plunking you into 500 of America's biggest companies.
If you can stomach some more risk, though, perhaps park some of your dollars in some fast-growing ETFs − though they can be more volatile.
However you do it, be sure that you have a solid retirement plan and that you're sticking with it, saving and investing for a comfortable future.
Selena Maranjian has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Vanguard S&P 500 ETF. The Motley Fool has a disclosure policy.
The Motley Fool is a USA TODAY content partner offering financial news, analysis and commentary designed to help people take control of their financial lives. Its content is produced independently of USA TODAY.
The $23,760 Social Security bonus most retirees completely overlook
Offer from the Motley Fool: If you're like most Americans, you're a few years (or more) behind on your retirement savings. But a handful of little-known "Social Security secrets"could help ensure a boost in your retirement income.
One easy trick could pay you as much as $23,760 more... each year! Once you learn how to maximize your Social Security benefits, we think you could retire confidently with the peace of mind we're all after. JoinStock Advisorto learn more about these strategies.
View the "Social Security secrets" »

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
2 High-Yield Dividend Stocks You Can Buy With $100 Now and Hold at Least a Decade
Key Points Shares of Brookfield Infrastructure and Novo Nordisk offer an average yield that is more than triple the market average. Novo Nordisk lowered its forward outlook in response to a problem that has most likely been resolved already. Brookfield Infrastructure's pipelines and data centers aren't particularly thrilling, but they do generate predictable cash flows. 10 stocks we like better than Novo Nordisk › Despite a recent dip in response to unfavorable economic data, the stock market's bull run seems unstoppable. From April 4 through Aug. 8, the S&P 500 index shot up a whopping 25.9%. For dividend-seeking investors, a buoyant stock market can be a little annoying. Stock prices rising faster than profits means most dividend payers offer unattractive yields. The average yield from dividend payers in the benchmark S&P 500 index is an unattractive 1.2% at recent prices. Most dividend yields aren't particularly desirable right now, but there are still some underappreciated gems hiding in plain sight. Novo Nordisk (NYSE: NVO) and Brookfield Infrastructure (NYSE: BIP)(NYSE: BIPC) offer an average yield of 3.9% at recent prices. Plus, they could raise their payouts at a mid-single-digit percentage, or better, every year from now until you want to retire. You don't have to be wealthy to put your money to work with these stocks. At recent prices, $100 is enough to buy a share of both. Here's why that looks like a great idea for folks who would like to grow their passive income streams. Novo Nordisk From the end of 2023 through Aug. 7, shares of Novo Nordisk lost more than half their value. Earnings reported by the Denmark-headquartered company that markets Ozempic and Wegovy have performed much better than the stock. If we ignore currency exchange rates, U.S. investors who buy the stock at recent prices would receive a 3.44% yield if Novo Nordisk holds the payout flat. Holding dividend payments steady isn't in this company's nature. From 2020 through 2024, it raised annualized dividend payments by 120% in its native currency. Shares of this drugmaker have been under intense pressure since management lowered its sales outlook for 2025. On Aug. 6, the company told investors to expect revenue to rise between 8% and 14% this year. That's much slower than the 13% to 21% range management provided in May. On the bottom line, management lowered its operating earnings growth outlook to a range of between 10% and 16% this year. This is a slower rate of growth than we had been expecting, but it's still pretty good for an established pharmaceutical business. Shares of Novo Nordisk have been beaten down to just 14.1 times trailing earnings. This valuation implies growth at a low single-digit percentage over the long run. I'd argue that profit growth of around 10% annually seems far more likely. During its initial launch, Novo Nordisk failed to produce enough Wegovy to meet demand, which allowed independent compounding pharmacies to fill in the gap. The Food and Drug Administration declared an end to the Wegovy shortage in February. Compounding pharmacies that have been fighting the decision in U.S. courts without success are a headwind that seems likely to subside. Brookfield Infrastructure Even if you haven't heard of Brookfield Infrastructure, there's a good chance your employer relies on at least one of its assets. This subsidiary of Brookfield Asset Management owns and operates critical infrastructure networks that facilitate the flow of freight, passengers, data, water, and energy. Shares of Brookfield Infrastructure have fallen by about 15% over the past three years, but its dividend payout has risen by 18.5% over the same time frame. At recent prices, the stock offers an unusually large 4.3% dividend yield. Investing in pipelines, fiber optic cables, railways, data centers, toll roads, and telecom towers receives significantly less attention than big tech's investments in artificial intelligence (AI). I'd argue that this is one of the safest AI stocks you can buy now. Nobody knows which large language models will become the most popular over the long run, but we can be sure they will require heaps of energy and data transmission. Brookfield Infrastructure's portfolio includes assets that provide both. During the second quarter, Brookfield Infrastructure reported funds from operations (FFO), a proxy for earnings used to evaluate asset-heavy businesses, that rose 5% year over year to $0.81 per share. This is heaps more than it needs to meet a quarterly dividend payout currently set at $0.43 per share and raise it much further. Adding some shares to a diversified portfolio looks like a nearly surefire way to generate heaps of dividend income over the long run. Do the experts think Novo Nordisk is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Novo Nordisk make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,060% vs. just 182% for the S&P — that is beating the market by 877.64%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Brookfield Infrastructure Partners and Novo Nordisk. The Motley Fool has a disclosure policy. 2 High-Yield Dividend Stocks You Can Buy With $100 Now and Hold at Least a Decade was originally published by The Motley Fool
Yahoo
4 hours ago
- Yahoo
Why Nektar Therapeutics Stock Popped 6% on Friday
Key Points Investors were reacting to the biotech's second-quarter earnings report. Revenue was higher than analysts expected, although the net loss was deeper than the consensus. 10 stocks we like better than Nektar Therapeutics › Biotech Nektar Therapeutics (NASDAQ: NKTR) unveiled its latest quarterly earnings after the stock market's close on Thursday, and the investor reaction was strong the following day. Happily for Nektar, it was largely positive, and the share price increased by 6% today. This was well higher than the 0.8% gain posted by the S&P 500 index. Sweet results In its second quarter, Nektar booked total revenue of just under $11.2 million, which was less than half of the nearly $23.5 million in the same period of 2024. All of this derived from noncash royalty revenue connected to the sales of future royalties. This isn't unusual for a biotech without a commercialized product that depends on royalties and other payouts from partners. Nektar added that its cash and investments in marketable securities stood at just under $176 million at the end of the quarter (June 30). That, plus the roughly $107.5 million it should reap from a recent secondary share issue, should fund its operations into the first quarter of 2027. Meanwhile, the company's net loss for the second quarter was slightly over $39 million, or $2.78 per share. On average, analysts were projecting Nektar would book $9.7 million in revenue and a net loss of only $0.20 per share. I should note here that it can be challenging for even the most experienced professionals to estimate the results of biotechs that don't draw meaningful revenue from commercialized products. On a fast track All that said, there are several potential tailwinds for Nektar just now, and the company wasn't shy about itemizing them in its earnings release. Among the more promising is the U.S. Food and Drug Administration granting its Fast Track designation for rezpegaldesleukin, Nektar's investigational drug targeting severe-to-very-severe alopecia areata (a skin disorder). Do the experts think Nektar Therapeutics is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Nektar Therapeutics make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,047% vs. just 181% for the S&P — that is beating the market by 865.68%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Nektar Therapeutics Stock Popped 6% on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Why Integral Ad Science's Stock Crushed the Market on Friday
Key Points All three revenue categories for the company saw year-over-year rises in its latest reported quarter. With that, it wasn't too hard for the company to score beats on both revenue and profitability. 10 stocks we like better than Integral Ad Science › The stock of digital advertising analysis company Integral Ad Science (NASDAQ: IAS) enjoyed a double-digit jump on Friday. The shares rose a hearty 12%-plus following the release of second-quarter earnings after market close on Thursday. That was far more than good enough to beat the benchmark S&P 500 index, which ticked up 0.8% Friday. A good client list Integral's revenue rose 16% year over year during the period to slightly north of $149 million. Much of this growth came from the company's optimization services, which drew nearly $68 million for a 16% rise. Measurement revenue also advanced, although at a more modest 8%, to $57 million. Bringing up the rear was publisher revenue, enjoying a 36% increase to over $24 million. The improvement on the bottom line was more impressive, with net income under generally accepted accounting principles (GAAP) more than doubling to $16.4 million ($0.10 per share) from the year-ago profit of $7.7 million. Both headline numbers were well above the consensus analyst estimates. On average, pundits tracking Integral stock were estimating the company would register a bit over $143 million on the top line and earn a GAAP profit of $0.04 per share. We live in a world awash with advertising, and the digital segment is particularly active. There is a right time/right place quality to Integral, which has secured heavyweight clients such as social media giant Meta Platforms and ride-sharing specialist Lyft. Topping up top-line guidance Compounding the solid second-quarter results, Integral also increased revenue guidance for the entirety of 2025. It now believes its total top line will come in at $597 million to $605 million. Adjusted earnings before interest, taxes, depreciation, and amortization are forecast to hit $208 million to $214 million. Should you invest $1,000 in Integral Ad Science right now? Before you buy stock in Integral Ad Science, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Integral Ad Science wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Meta Platforms. The Motley Fool recommends Integral Ad Science and Lyft. The Motley Fool has a disclosure policy. Why Integral Ad Science's Stock Crushed the Market on Friday was originally published by The Motley Fool